AIMN Aimwell Partners Inc.

$AIMN these OTC junk is all it is junk you buy it better be at .0001 or 0002. Or you go broke.thr mmm never let it go up unless they have shares to dump

$AIMN Great potential here. Penny land will happen when they release a solid revenue PR with some numbers to back it.

$AIMN - about ready to break out - this has the potential to be between 10X to 100X current value in the next few months

$AIMN Micro penny flippers are always best to flush out daily. The volume is the support however. Going back up.

$AIMN Now that it has cleared the 50 Day MA it seems to have very little resistance until .0078.. volume has found this one..

$AIMN Shell Company 😳😳😳 Not Really Selling the Idea to the Healthcare Industry. I think He and the Doc in with him on this( It is just 1 dude and his idea) may have givin 1 Hospital free services to have some clout in their scheme.... sucks... Shareholders cannot comment on X to their posts...

🚀 $AIMN AimwellBio is building the trusted intelligence layer healthcare AI has been missing. With the Trustr behavioral AI patent (Oxford science + Sanofi asthma pilot), AIMWELL Cortex, and the Federated Health Intelligence Network (FHIN), they’re focused on source-verified, confidence-scored intelligence while cutting through AI hallucinations in biopharma and clinical decisions. They’re also expanding into a Founding Physician Cohort around GLP-1 and metabolic care. This is real infrastructure for verified healthcare intelligence — not just another AI story. Watching this one closely. 💪❤️ #AIMN #HealthcareAI #Biotech #OTC

$AIMN here is the ugly truth about share structure... they just kept adding shares, then did a Reverse Split and then just kept on adding more... we are funding One Man's Lavish Life through a non existant revenue idea for a business.

$AIMN this is pretty sad.... one man made up a business( out of thin air)on the back of the failure/fraudulent company with public trading RONN, got a doctor to go in with him on the story and now here we are... that's it.. maybe it can pump or grow... lot of people's money got compromised here....

$AIMN • Public Float: ~179.20M shares • Shares Outstanding: ~330.10M 300 million restricted Till August 2027.

$AIMN Chart still bullish with support at .0025..if the open is quiet might be a nice spot for bids.. yesterday was an indecisive day so might be a full day before next leg up..

$AIMN I’m telling you we have a real product here people for a massive life changing profit. Let’s go !! This is going to run. Dr. Christopher A. Jones (Oxford PhD) brings serious institutional clout to AimwellBio, backed by a proven track record of bringing cutting-edge AI directly into the big pharma arena. Before monetizing his core Trustr platform in a $10M transaction with Aimwell Partners (AIMN), Dr. Jones successfully took his proprietary behavioral algorithms through commercial pilot testing with global pharmaceutical titan Sanofi to optimize patient engagement in asthma management. Validated by real-world testing with a multi-billion-dollar pharma leader and recognized by the Academy of Managed Care Pharmacy (AMCP), Dr. Jones’s decade of IP development isn't just theoretical science—it’s pharma-tested technology built to scale across the global biopharma landscape.